High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients

Vincent van der Velden, N Boeckx, I Jedema, Jeroen te Marvelde, Patricia Hoogeveen, M Boogaerts, Jacques Dongen

Research output: Contribution to journalArticleAcademicpeer-review

106 Citations (Scopus)
73 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)983-988
Number of pages6
JournalLeukemia
Volume18
DOIs
Publication statusPublished - 2004

Research programs

  • EMC MM-02-72-03

Cite this